InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert

• Expands library of proprietary cannabinoid analogs for pharma R&D
• Research collaboration initiated to screen analogs for therapeutic uses

InMed Pharmaceuticals Inc.(Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the publication of a patent application in North America for several cannabinoid analogs. This patent application has broad claims directed to their molecular structure, uses and methods of manufacturing.

Entitled “Cannabinoid Analogs and Methods for their Preparation”, the patent application describes several new cannabinoid-related chemical compounds that have not been previously described. If granted, the broad patent application allows for the creation of several variations of novel cannabinoid compounds, producing a robust library of proprietary new chemical entities (‘NCEs’).

Scientists at BayMedica, LLC, InMed’s subsidiary in the US, designed and produced these cannabinoid analogs. These NCEs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cannabinoid with modifications that may make them preferred candidates to treat specific diseases.

We believe rare cannabinoids hold tremendous therapeutic potential that may address a number of unmet medical needs. This patent covers the selective modification of naturally occurring cannabinoids to target specific properties for pharmaceutical development. Such patent protection is an important component to ensure long-term commercial exclusivity as we continue to invest in R&D.

Eric Hsu, SVP, Pre-Clinical Research and Development for InMed

InMed has initiated a research collaboration with the Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila (Italy) in the laboratory of Dr. Mauro Maccarrone, an international expert in cannabinoid research and founding member of the European Cannabinoid Research Alliance. He is also the 2007 recipient of the International Association for Cannabinoid Medicines’s prestigious Ester Fride Award for Basic Research, and the 2016 recipient of the International Cannabinoid Research Society’s prestigious Mechoulam Award. Dr. Maccarrone’s lab will be screening the Company’s novel cannabinoid analogs to investigate pharmacological properties and potential therapeutic uses.

Creating a robust patent library of NCEs

The patent application covers technology that allows for the creation of libraries of NCEs that can be compared to other drugs in order to select candidates for advancement. The cannabinoid analogs were manufactured in a biosynthetic process using the yeast S. cerevisiae, which is commonly used to produce therapeutic biologicals and vaccines.

Filing this patent application in a number of global jurisdicitions further emphasizes the Company’s commitment towards developing NCEs and enhancing rare cannabinoids R&D opportunities.

Why pursue cannabinoid analogs?

Unlike natural cannabinoids isolated from the plant which are not patentable, these cannabinoid analogs are patentable. Benefits may include:

• Targeting certain physiological outcomes in specific diseases;
• Improving upon the safety profile of the natural cannabinoids;
• Enhancing the ability to integrate with specific delivery technologies; and
• Protecting the long-term research investment and commercial opportunities.

Learn more about InMed’s Cannabinoid Analogs:
Novel Patentable Cannabinoid Analogs | InMed Pharmaceuticals

Learn more about InMed’s Cannabinoids in Development: https://www.inmedpharma.com/pharmaceutical/cannabinoids-in-development/

To view the original press release in its entirety click here